Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.74 USD
Change Today -0.09 / -4.92%
Volume 3.0M
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

mei pharma inc (MEIP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/28/14 - $13.98
52 Week Low
03/27/15 - $1.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEI PHARMA INC (MEIP)

Related News

No related news articles were found.

mei pharma inc (MEIP) Related Businessweek News

No Related Businessweek News Found

mei pharma inc (MEIP) Details

MEI Pharma, Inc., an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company’s lead drug candidate is Pracinostat, an orally available histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia. Its clinical development pipeline also includes ME-344, an isoflavone-derived mitochondrial inhibitor drug candidate that is in Phase Ib trial to treat lung and ovarian cancer; and PWT143, an oral inhibitor of phosphatidylinositide 3-kinase, which is in pre-clinical stage for the treatment of cancer. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited.

mei pharma inc (MEIP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $482.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $284.6K
Chief Medical Officer
Total Annual Compensation: $153.6K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $70.6K
Compensation as of Fiscal Year 2014.

mei pharma inc (MEIP) Key Developments

MEI Pharma, Inc. Announces Data from Randomized Phase II Clinical Study of Pracinostat In Front-Line Myelodysplastic Syndrome

MEI Pharma, Inc. announced data from a randomized Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). The double-blind, placebo-controlled study enrolled a total of 102 patients, randomized one-to-one, at 19 sites in the U.S. The combination of Pracinostat and azacitidine showed no difference in the rate of complete remission (CR), the study's primary endpoint, compared to azacitidine alone. Data from event-driven endpoints, including duration of response, event and progression free survival and overall survival, are immature and will require longer follow-up in order to achieve meaningful conclusions. There were no new or unexpected toxicities observed in the study. Fatigue, gastrointestinal toxicities and myelosuppresion occurred more frequently in the combination group and resulted in a higher rate of drug discontinuations compared to azacitidine alone. The company expects to present full results of the study at a scientific meeting later this year. Pracinostat is an oral histone deacetylase (HDAC) inhibitor that has been tested in a number of Phase I and Phase II clinical studies in advanced hematologic disorders and solid tumor indications. Pracinostat has been generally well tolerated in more than 300 patients, with manageable side effects often associated with drugs of this class, notably fatigue. Pracinostat has exhibited pharmacokinetic properties in these studies that compare favorably to other oral HDAC inhibitors, including Zolinza ® (vorinostat) and Farydak ® (panobinostat).

MEI Pharma, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:40 AM

MEI Pharma, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:40 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Daniel P. Gold, Chief Executive Officer, President and Director.

MEI Pharma, Inc. Reaches Response Milestone in Phase II Clinical Trial of Pracinostat in Refractory Myelodysplastic Syndrome

MEI Pharma, Inc. announced that the clinical response milestone has been reached in the company's ongoing Phase II study of its investigational drug candidate Pracinostat in combination with a hypomethylating agent (HMA) in patients with myelodysplastic syndrome (MDS) who previously failed treatment with single-agent HMA. Of the first 28 patients who received Pracinostat in combination with azacitidine (marketed as Vidaza) or decitabine (marketed as Dacogen) after progressing while being treated with the same HMA alone, three have now achieved clinical responses, one partial response (PR) and two marrow complete responses (mCR), exceeding the pre-specified clinical improvement rate for expansion of study enrollment. The primary endpoint of the refractory MDS study is clinical improvement rate, defined as the proportion of patients with CR, mCR, PR and hematologic improvement. Secondary endpoints include overall response rate, duration of response, transfusion independence, progression-free survival and overall survival. The combination of Pracinostat and azacitidine or decitabine has been generally well-tolerated in the study, with no unexpected toxicities. The most common treatment-emergent adverse events include anemia, fatigue and gastrointestinal disorders.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MEIP:US $1.74 USD -0.09

MEIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MEIP.
View Industry Companies

Industry Analysis


Industry Average

Valuation MEIP Industry Range
No financial data is available for MEIP.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEI PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at